Why CLDX Stock dropped -3.52% Today — RQD Quant Desk Flash

CLDX scores 28 out of 100, a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

• Fundamental Cash Engine (9 / 20): this pillar reflects ROIC of -35% and FCF yield of -9.1%. Both figures indicate the business is consuming rather than generating cash relative to its capital base and market value.
• Whale 13F Flow (5 / 20): institutional accumulation and options positioning score low. The underlying 13F detail is not itemized in the source data.
• Insider Conviction (3 / 20): SEC Form 4 and Congressional PTR cluster flow scores low. No individual transactions are itemized in the source data.
• Macro Regime Fit (3 / 20): beta of 1.0 and sector sensitivity score low.
• Forensic Balance Sheet (8 / 20): Altman Z 20.25, Piotroski F 3/9, and Debt/Equity 0.5 are cited. The high Altman Z is offset by a weak Piotroski score.

For a prospective investor, the upside case rests on the 87.1% gross margin and the 52-week range of $22.1 to $45.14, which places the current price of $29.89 in the lower-middle portion of that band. The reported operating margin of -60% and net margin of -60% mean any investment thesis depends on future operating improvement rather than current profitability. The combined RQD pillar scores, all below 50% of their maximums, point to weak alignment across fundamentals, flows, and insider behavior at this time.

Celldex Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry,. Reported revenue was $1.5M in FY 2025, $7.0M in FY 2024, and $6.9M in FY 2023, . — for further detail on how the company monetizes its offerings.

The company reported operating losses in each period shown, with FY 2025 operating income of -$287.4M against revenue of $1.5M. Per the market data, gross margin is 87.1%, while operating and net margins are each -60%, and ROIC is -35%. The Altman Z-Score is 20.25 and the Piotroski F-Score is 3 of 9, with Debt/Equity of 0.5. The balance sheet posture reflects a high Altman Z alongside weak Piotroski quality signals and reported cash of $28.9M at FY 2025 year-end.

• 🐂 Primary Bull Case: Gross margin of 87.1% and a CATALYST-flagged news item indicate strong unit economics and potential upside if operating losses narrow. With Fundamental Cash Engine at 9/20 (ROIC -35.0%, FCF yield -9.10%) and Institutional Whale Flow at 6/20, sustained execution supports upside toward the top of the $22.10 – $45.14 52-week range.
• 🐻 Primary Bear Case: Free cash flow of -$213.7M against $28.9M of cash and an RQD score of 28 (Grade E) point to significant forensic and liquidity risk. Investors must weigh current valuation against -60.0% operating margins and a 1.00 macro beta if sector demand softens.

Operating in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), CLDX carries a macro regime beta of 1.00 and gross margin of 87.1%.

• Key Question #1: What is the nature and status of the shareholder investigation referenced in the news flow?
• Key Question #2: What cash runway is implied by the $28.9M in FY 2025 cash against the -$213.7M free cash flow reported that year?
• Key Question #3: How sensitive is CLDX's 87.1% gross margin and equity valuation to Health Care demand cycles and macro interest-rate shifts (Beta 1.00)?